GET THE APP

Peramivir analogs bearing hydrophilic substituent to overcome vir | 37699
Organic Chemistry: Current Research

Organic Chemistry: Current Research
Open Access

ISSN: 2161-0401

+44 1478 350008

Peramivir analogs bearing hydrophilic substituent to overcome viral resistance


3rd International Conference on Organic and Inorganic Chemistry

July 17-19, 2017 Chicago, USA

Din-Chi Chiu and Jim-Min Fang

National Taiwan University, Taiwan

Posters & Accepted Abstracts: Organic Chem Curr Res

Abstract :

Influenza an acute respiratory disease remains to impact public health greatly. One of the envelope proteins called Neuraminidase (NA) acts as a critical role in replication cycle of influenza virus, and its inhibitors such as oseltamivir and peramivir have been widely used for clinical treatment of influenza infections. Despite NA��?s high conservation, certain mutations such as H274Y and R292K have been observed, thus leading to suppression of drug effectiveness. Referring to the co-crystal structure of NA and peramivir or oseltamivir, the drop of drug activity can be attributed to those unfavorable interactions between the hydrophobic substituents, 3-pentyl or 3-pentoxyl, on NA inhibitors and amino acid residues of NA. Consequently, peramivir derivatives bearing hydrophilic side chain were designed and synthesized in order to overcome drug resistance. (Fig.1) Gratifying, a pioneering method with complete consumption of the dipolariphile was developed by using reduced amount of nitrile oxide 1, 3-dipole to conduct the 1, 3- dipolar cycloaddition reactions. Aside from discovery of an alternative synthetic route, alleviated drug resistance is observed on analogs with various hydrophilic substituents, and improvement of inhibitory effects toward mutant viruses can be expected.

Biography :

Din-Chi Chiu has received his BS from Department of Material Science and Engineering, National Chiao Tung University. He is motivated by the passion on organic synthesis and drug discovery. He’s currently majoring Chemistry in National Taiwan University and conducting research about development of new anti-influenza agent as his master study.

Email: dylan82729@gmail.com

Top